Xue Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xue Wang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Zhang
Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden
1 shared publication - Choong Yong Ung
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA
1 shared publication - Cristina Correia
Department of Oncology, Mayo Clinic, Rochester, MN, USA
1 shared publication - Hu Li
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA
1 shared publication - Jessica Chalk
Mayo Clinic, Jacksonville, FL USA
1 shared publication - Joseph Swaroop Reddy
Mayo Clinic Florida
1 shared publication
Latest Publications
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Network‐based pipeline guides knowledge‐driven prioritization and validation of therapeutic target discovery for Alzheimer’s disease
Background: Context‐specific networks can capture functionally important genes that may not be differentially expressed. Leveraging seven different gene expression datasets of Alzheimer’s disease (AD) and healthy control brains, we constructed a novel pipeline that includes such network analysis, augmented by in vivo validations and in silico drug repurposing to facilitate prioritization of AD therapeutic targets.Method: We utilized publicly available gene expression data from 733 AD and 454 control brains across 7 datasets and the NetDecoder (PMID: 26975659) network biology platform to build context‐specific networks. Based on the known protein‐protein interaction and gene expression correlations, information flow from the top differentially expressed genes (DEG) to transcriptional regulator genes was calculated using a process‐guided flow algorithm. Genes with the greatest informational flow changes across AD cohorts were systematically prioritized. We next validated these genes in a medium‐throughput screen of a tau‐transgenic Drosophila model (PMID: 11408621). Further, we identified existing small‐molecule drugs to target the candidate genes utilizing curated databases.Results: A total of 14 context‐specific networks were constructed across 7 datasets. We found AD‐related genes, such as APP, to have high flow differences between AD and control networks and high connectivity. Notably, many such genes were not DEGs between AD and control, suggesting that the information flow captures novel aspects of AD pathophysiology. We nominated 224 unique genes with the greatest flow differences for functional validation. We screened 111 of the 224 candidate genes with readily available, high‐confidence orthologs in Drosophila. We identified genes that suppress (N = 68) or enhance (N = 27) tau‐related neurodegeneration in this model. We confirmed the effects of previously nominated genes, such as HDAC1, which enhances tau‐neurodegeneration if overexpressed and suppresses it if knocked down. We also identified and validated additional therapeutic targets. Lastly, we applied a network‐proximity‐based algorithm and identified small molecule drugs for the candidate genes.Conclusion: We present a novel pipeline that integrates analytic approaches, experimental validation, and drug repurposing to facilitate therapeutic discovery in AD. We applied this pipeline and nominated previously known and novel genes implicated in AD pathogenesis. Our pipeline demonstrates a cross‐species, systems‐level approach to therapeutic nomination in AD and related neurodegenerative diseases.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Open AccessNetwork‐based pipeline guides knowledge‐driven prioritization and validation of therapeutic target discovery for Alzheimer’s disease
Background: Context‐specific networks can capture functionally important genes that may not be differentially expressed. Leveraging seven different gene expression datasets of Alzheimer’s disease (AD) and healthy control brains, we constructed a novel pipeline that includes such network analysis, augmented by in vivo validations and in silico drug repurposing to facilitate prioritization of AD therapeutic targets.Method: We utilized publicly available gene expression data from 733 AD and 454 control brains across 7 datasets and the NetDecoder (PMID: 26975659) network biology platform to build context‐specific networks. Based on the known protein‐protein interaction and gene expression correlations, information flow from the top differentially expressed genes (DEG) to transcriptional regulator genes was calculated using a process‐guided flow algorithm. Genes with the greatest informational flow changes across AD cohorts were systematically prioritized. We next validated these genes in a medium‐throughput screen of a tau‐transgenic Drosophila model (PMID: 11408621). Further, we identified existing small‐molecule drugs to target the candidate genes utilizing curated databases.Results: A total of 14 context‐specific networks were constructed across 7 datasets. We found AD‐related genes, such as APP, to have high flow differences between AD and control networks and high connectivity. Notably, many such genes were not DEGs between AD and control, suggesting that the information flow captures novel aspects of AD pathophysiology. We nominated 224 unique genes with the greatest flow differences for functional validation. We screened 111 of the 224 candidate genes with readily available, high‐confidence orthologs in Drosophila. We identified genes that suppress (N = 68) or enhance (N = 27) tau‐related neurodegeneration in this model. We confirmed the effects of previously nominated genes, such as HDAC1, which enhances tau‐neurodegeneration if overexpressed and suppresses it if knocked down. We also identified and validated additional therapeutic targets. Lastly, we applied a network‐proximity‐based algorithm and identified small molecule drugs for the candidate genes.Conclusion: We present a novel pipeline that integrates analytic approaches, experimental validation, and drug repurposing to facilitate therapeutic discovery in AD. We applied this pipeline and nominated previously known and novel genes implicated in AD pathogenesis. Our pipeline demonstrates a cross‐species, systems‐level approach to therapeutic nomination in AD and related neurodegenerative diseases.
- Open Access
- 29 October 2021
- Published by Springer Nature in Research Square
Risk Prediction Model of Postoperative Venous Thrombosis of Ovarian Cancer
Objective To investigate the influencing factors of venous thromboembolism (VTE) after ovarian cancer surgery, and construct its prediction model. Methods A total of 67 patients with ovarian cancer who developed VTE after surgery were selected from October 2008 to June 2020 in the Department of Obstetrics and Gynecology, First Hospital of Lanzhou University, and conducted a retrospective study with 100 patients without VTE after the operation who were confirmed by imaging during the same period. The clinical data of two groups of patients were analyzed and compared, and the risk prediction model was established. The ROC curve was drawn to evaluate the prediction effect of the model. Results Univariate analysis showed that there were statistically significant differences in age, menopausal status, hypertension, neoadjuvant chemotherapy, FIGO staging, lymph node metastasis, operation time, preoperative plasma FIB and D-dimer between the thrombosis group and the non-thrombosis group;The results of multivariate analysis showed that old age, neoadjuvant chemotherapy, late FIGO staging, high levels of plasma FIB and D-dimer before surgery are independent risk factors for VTE after ovarian cancer surgery. Construct a prediction model based on the results of multivariate regression analysis: Logit(P) = 0.053 × age + 0.917 × neoadjuvant chemotherapy + 0.956 × tumor FIGO staging + 0.398 × preoperative plasma FIB + 0.531 × preoperative D-dimer -7.679 ( Neoadjuvant chemotherapy, yes=1, no=0; tumor FIGO stage Ⅰ+Ⅱ=1, Ⅲ+Ⅳ=2; age, preoperative plasma FIB and D-dimer are actual values). The ROC curve analysis shows that the AUC value of the model is 0.773, the sensitivity is 74.6%, the specificity is 71.0%, and the total prediction accuracy rate is (78+39)/167=0.701. Conclusions Age, neoadjuvant chemotherapy, tumor FIGO staging, preoperative plasma FIB and D-dimer can be used as reliable indicators to predict the occurrence of postoperative VTE in patients with ovarian cancer. The constructed prediction model has good risk prediction ability, It has certain clinical application value.
- 29 October 2021
- Published by Springer Nature in Research Square
Open AccessRisk Prediction Model of Postoperative Venous Thrombosis of Ovarian Cancer
Objective To investigate the influencing factors of venous thromboembolism (VTE) after ovarian cancer surgery, and construct its prediction model. Methods A total of 67 patients with ovarian cancer who developed VTE after surgery were selected from October 2008 to June 2020 in the Department of Obstetrics and Gynecology, First Hospital of Lanzhou University, and conducted a retrospective study with 100 patients without VTE after the operation who were confirmed by imaging during the same period. The clinical data of two groups of patients were analyzed and compared, and the risk prediction model was established. The ROC curve was drawn to evaluate the prediction effect of the model. Results Univariate analysis showed that there were statistically significant differences in age, menopausal status, hypertension, neoadjuvant chemotherapy, FIGO staging, lymph node metastasis, operation time, preoperative plasma FIB and D-dimer between the thrombosis group and the non-thrombosis group;The results of multivariate analysis showed that old age, neoadjuvant chemotherapy, late FIGO staging, high levels of plasma FIB and D-dimer before surgery are independent risk factors for VTE after ovarian cancer surgery. Construct a prediction model based on the results of multivariate regression analysis: Logit(P) = 0.053 × age + 0.917 × neoadjuvant chemotherapy + 0.956 × tumor FIGO staging + 0.398 × preoperative plasma FIB + 0.531 × preoperative D-dimer -7.679 ( Neoadjuvant chemotherapy, yes=1, no=0; tumor FIGO stage Ⅰ+Ⅱ=1, Ⅲ+Ⅳ=2; age, preoperative plasma FIB and D-dimer are actual values). The ROC curve analysis shows that the AUC value of the model is 0.773, the sensitivity is 74.6%, the specificity is 71.0%, and the total prediction accuracy rate is (78+39)/167=0.701. Conclusions Age, neoadjuvant chemotherapy, tumor FIGO staging, preoperative plasma FIB and D-dimer can be used as reliable indicators to predict the occurrence of postoperative VTE in patients with ovarian cancer. The constructed prediction model has good risk prediction ability, It has certain clinical application value.